Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 13, 2007. The document serves as a notification of transactions involving the company's Ordinary shares and American Depositary Shares (ADSs) by Directors and Persons Discharging Managerial Responsibility, in accordance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly limited to executive share transaction disclosures and does not contain financial performance data.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details specific share transactions by three executives:
- Dr. J-P Garnier: Sold 17,411 Ordinary Share ADRs on February 13, 2007, at $57.37 per ADR. His remaining shareholding is equivalent to more than 17 times his annual basic salary.
- Mr. R Bondy: Exercised 3,620 SmithKline Beecham UK Senior Executive Bonus Investment Rights on February 13, 2007. He sold 1,466 shares at GBP14.65 per share and retained 2,154 shares.
- Mr. J Clarke: Exercised nil-price options on 8,103 Ordinary shares on February 12, 2007. He sold 3,323 shares at GBP14.63 per share and retained 4,780 shares.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document contains no forward-looking statements or risk assessments.
Key Facts for Investor Verification
- Verify the total shareholding of Dr. J-P Garnier to confirm it remains above the 17x annual salary threshold post-transaction.
- Confirm the exercise price and retention details for Mr. Bondy's and Mr. Clarke's option exercises.
- Note that this filing does not reflect the company's broader financial performance for the period.